Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use

Andrew J McBride, Kath Williamson, Trudi Petersen

Abstract
Three case reports are presented of nalbuphine hydrochloride dependence meeting DSM III-R and ICD10 criteria for opioid dependence. Nalbuphine hydrochloride is being obtained from illicit sources and used by those using performance enhancing drugs. In some cases this leads to opioid dependence. There is a potential risks of crossover between the misuse of drugs of performance and the misuse of psychoactive drugs by injection. Further research into the dependence potential of nalbuphine and the extent of the crossover between steroid misuse and other psychoactive drug misuse is required. The legal status of nalbuphine should be reviewed in the light of its availability on the black market.


Key terms: nalbuphine hydrochloride; anabolic steroids; opioid dependence.

We report three anabolic steroid users presenting to a well steroid user clinic,1 complaining of nalbuphine hydrochloride dependence. Nalbuphine (Nubain) is an opioid agonist/antagonist analgesic licensed for the treatment of moderate to severe pain. The recommended daily dosage is 10-20 mg for a 70 kg man. DuPont Pharmaceuticals manufacture the drug in injectable form only, for subcutaneous, intramuscular, or intravenous use. Nalbuphine is not controlled under the Misuse of Drugs Act (1971) in the United Kingdom, nor classified as a narcotic in any country.2

Case reports

CASE 1
Mr A, a 27 year old divorced anabolic steroid dealer and unemployed roofer, presented complaining of withdrawal symptoms within hours of discontinuing nalbuphine. He had used black market nalbuphine over a nine month period, initially 10 mg three times daily subcutaneously, to relieve pain from a rugby injury. He initially experienced no symptoms of dependence, but felt relaxed and “spaced out” by the drug. Gradually, he recognised tolerance to the drug’s effects, and irritability and abdominal discomfort between doses. He changed to intravenous use and gradually increased the dose to 160–200 mg daily.

Two attempts to stop nalbuphine had resulted in nausea, abdominal cramps, diarrhoea, shaking, and sweating. Increasing intensity on the second day of abstinence led to further use of nalbuphine and resolution of symptoms.

Mr A had used anabolic steroids intermittently for five years. During his 9 month period of nalbuphine use, he used clenbuterol, three tablets daily, testosterone propionate, 250 mg on alternate days, and human chorionic gonadotrophin, every 11 days. He had not changed this regimen when stopping the nalbuphine.

He had smoked cannabis regularly for several years, and misused temazepam over a six week period, including by intravenous injection, 5 years previously.

CASE 2
Mr B, a 22 year old single unemployed gym manager, presented complaining of withdrawal symptoms on stopping nalbuphine and an overwhelming preoccupation with the drug.

A competitive bodybuilder, Mr B had used black market nalbuphine for two years, initially to allow him to train “through the pain barrier” (to train despite musculoskeletal pain), and to keep calm preparing for competition. Nalbuphine use had always been intravenous: an “unbelievable” (pleasurable) experience. His maximum daily dose had been 100 mg, but at presentation he had deliberately reduced this to 40 mg in three divided doses.

Mr B recognised a problem with nalbuphine when he experienced mood swings and irritability as the effects wore off. He had attempted to stop the drug on one occasion and experienced sweating, tremor, abdominal cramps, and “flu-like” symptoms. He therefore restarted it after three days, with immediate alleviation of his symptoms. A teetotaller, Mr B had initially used nalbuphine in conjunction with anabolic steroids, clenbuterol, ephedrine, and tamoxifen, all to aid bodybuilding. He had used only nalbuphine for 12 months. There was no other history of psychoactive drug misuse.

CASE 3
Mr C, a 26 year old gym owner, had used black market nalbuphine intramuscularly for two years, initially for pain from a back injury. He had used the drug intravenously for only 11 days when he attended clinic, during which...
time he had increased the dose rapidly to 100–120 mg in eight injections daily. He felt unable to control his use and described strong cravings both for nalbuphine and injecting. He developed stomach cramps four hours after each injection and had never allowed any further symptoms to develop.

When first seen Mr C was also using illicit amphetamine sulphate powder, approximately 0·5 g daily orally and 1·75 g of cannabis daily. He had used anabolic steroids in the past, but not for two years. Each of the three cases fulfilled DSM3-R (304·0) and ICD 10 (F11·24) criteria for opioid dependence.

Discussion
Neither a Medline search nor the manufacturers identified any reports of nalbuphene dependence using recognised diagnostic criteria. These cases are also the first reports of opioid dependence resulting from drug use connected with competitive sports. McGarity reported treating six patients within one year “abusing either Nubain or Stadol.” Two were considered by the author to be both psychologically and physiologically dependent. There has been one further case report of a 44 year old male physician, “addicted” to nalbuphine and diphenhydramine, with a six month history of intramuscular and subcutaneous injection. No further details of the cases were given. Up to 1985 there had been four notifications to the manufacturers of alleged nalbuphene “dependence,” but no reports of “street use.”

A press report has claimed that nalbuphene use by steroid users is the “latest drugs craze to sweep... gyms” in the south west of England (Western Daily Press, 21 June 1994), and the authors have had enquiries from drugs agencies across England and Wales which have identified further individual cases of nalbuphene misuse or dependence, always anabolic steroid users, and always accompanied by anecdotal information of much more widespread use. On the black market at 1994 prices, nalbuphene cost £25–45 for ten 20 mg ampoules.

Users have reported several reasons for taking nalbuphene: to overcome musculoskeletal pain, despite the risk of injury, to keep calm before competition, and to take part in sport or training after injury. Less understandably, an antitropical effect has been claimed for nalbuphene, which has also been used to induce sleep following growth hormone use, to enhance the effects. All three individuals described here took doses of nalbuphene above the recommended maximum. Unpleasant subjective effects have been described with doses above 147 mg, but such symptoms did not occur in our cases. Before they became addicted to nalbuphene all three men had previously used drugs intramuscularly, and one had used it intravenously. The high doses and choice of the intravenous route may reflect the evolving process of opioid dependence, but may also have contributed to the development of dependence symptoms, particularly in case 3, in which doses increased very rapidly after the change to intravenous use.

No case had experienced the withdrawal symptoms associated with anabolic steroids, suggesting that their symptoms can properly be attributed to the nalbuphene. The only published evaluation of abuse potential during chronic administration of nalbuphene was limited to six prisoners with a history of “opiate abuse,” given the drug subcutaneously. Nalbuphene produced “some opiate-like effects” and 4 to 6 mg of naloxone precipitated an opioid abstinence syndrome in all six subjects.

In the United States two studies have shown positive correlations between anabolic steroid use and use of other illicit drugs in young people, but opioid use is not referred to specifically. The extent of anabolic steroid use by polydrug users in Britain is largely unknown, as is the extent of crossover from steroid use to other drug use.

Two cases of HIV infection associated with intramuscular use of anabolic steroids have been reported and it has been predicted that within a decade HIV infected anabolic steroid users might be presenting to services. The polydrug use prevalent in the risk group of cross infection, puts the anabolic steroid user at increased risk of contracting HIV and hepatitis, and the non-steroid user at potential risk of Jakob-Creutzfeld disease.

These cases suggest a need for further research into the relation between anabolic steroid and other drug use, and the extent of high risk behaviour. It has been asked why the American Food and Drug Administration released nalbuphene without controlled status, while “in the real world” patients were becoming dependent. The dependence potential of nalbuphene needs to be investigated further. The legal status of the drug should be re-examined in the light of this evidence that the drug has entered the black market.